Loading...
Loading...
According to Brean Murray Carret, Vivus
VVUS is upgraded to Hold.
Brean Murray Carret said that the Qnexa AdComm panel voted 20 to 2 to approve the drug, and such overwhelming support for post marketing safety trials rather than further Phase 3 safety trials leads us to believe that the FDA will probably grant approval in April. “Our rating, therefore, has been upgraded to Hold, and VVUS has been removed from our Near-Term Conviction Focus list.”
Vivus closed yesterday at $10.55.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in